Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6181311 | 1.00 | KDM4E (0.41) | KDM4ELMNABLMNPSR1CYP3A4 | |
| SCHEMBL6718396 | 0.98 | KDM4E (0.40) | KDM4ELMNABLMNPSR1CYP3A4 | |
| SCHEMBL9032838 | 0.81 | KMT2A (0.47) | KDM4EALDH1A1MAP3K7TAB1GAA | |
| SCHEMBL7318845 | 0.81 | MAP3K7 (0.39) | MAP3K7TAB1 | |
| SCHEMBL10540316 | 0.81 | MAP3K7 (0.39) | MAP3K7TAB1 | |
| SCHEMBL9326981 | 0.79 | KDM4E (0.46) | KDM4ELMNABLMNPSR1CYP3A4 | |
| SCHEMBL6181182 | 0.78 | CA12 (0.46) | KDM4ECYP3A4ALDH1A1GAAHCAR2 | |
| SCHEMBL6726458 | 0.78 | CA12 (0.46) | KDM4ECYP3A4ALDH1A1GAAHCAR2 | |
| SCHEMBL9129568 | 0.78 | KDM4E (0.41) | KDM4ELMNABLMNPSR1CYP3A4 | |
| SCHEMBL31324241 | 0.78 | KDM4E (0.41) | KDM4ELMNABLMNPSR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765063-B2 | Amido compounds as RORγt modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-9765063-B2 | Amido compounds as RORγt modulators and uses thereof | NEW YORK UNIVERSITY (US) | 2017-09-19 | — | — | US | disclosed |
| US-20150057278-A1 | AMIDO COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| US-20150057278-A1 | AMIDO COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-26 | — | — | US | disclosed |
| WO-2013036912-A2 | AMIDO COMPOUNDS AS RORϒTMODULATORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-2499162-A2 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 Pharma GmbH (DE) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011060206-A2 | MATERIAL AND METHODS FOR TREATING OR PREVENTING HER-3 ASSOCIATED DISEASES | U3 PHARMA GMBH (DE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| EP-1000932-B9 | AROMATIC RING DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1458686-A1 | BENZOCYCLODECANE DERIVATIVES WITH ANTITUMOR ACTIVITY | Pharmacia Italia S.p.A. (IT) | 2004-09-22 | — | — | EP | disclosed |
| EP-1000932-B1 | AROMATIC RING DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055861-A1 | BENZOCYCLODECANE DERIVATIVES WITH ANTITUMOR ACTIVITY | PHARMACIA ITALIA SPA (IT) | 2003-07-10 | — | — | WO | disclosed |
| US-6242474-B1 | SULFONYLCARBAMOYLALKYLIMIDAZOLE DERIVATIVES; ANTIDIABETIC AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-06-05 | — | — | US | disclosed |
| EP-1000932-A1 | AROMATIC RING DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057278-A1 | AMIDO COMPOUNDS AS RORyT MODULATORS AND USES THEREOF | RORB, RORA, RORC | KDM4E 4657/4885LMNA 3580/4885BLM 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.